Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management
A subset analysis of the East German Lymphoma Study Group randomized trial of rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (R‑CHOP) versus bendamustine/rituximab (BR) showed a 95% response rate in both groups, but progression‑free survival was 36 months for R‑CHOP and not reached for BR.
Waldenström macroglobulinemia is a rare hematologic malignancy characterized by an IgM‑associated lymphoplasmacytic lymphoma. Often, it is associated with an indolent disease course, and many patients are candidates for careful monitoring. As many patients present with advanced age and nonspecific constitutional symptoms, careful consideration should be given to treatment decisions, including when and how to treat for maximized clinical benefit with minimal toxicity. This article provides an evidence‑based practical approach to appropriate monitoring of the asymptomatic patient and management of symptomatic patients who require treatment for this rare malignancy.
This evidence supports the recommendation of BR as a standard frontline therapy for Waldenström macroglobulinemia, highlighting its superior efficacy and lower toxicity compared to R‑CHOP.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Waldenström Macroglobulinemia Clinical Trials
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia